06 Oct 2025 Onco3R Therapeutics Announces Completion of First Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671 and Oral Presentation at UEGW 2025 Multiple categories
24 Sep 2025 Enhertu plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer Multiple categories
25 Aug 2025 argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG Multiple categories
23 Jul 2025 KU Leuven researchers identify promising drug for treating severe malaria Multiple categories
30 Jun 2025 argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes Multiple categories
20 Jun 2025 argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy Multiple categories
05 Jun 2025 AstriVax Therapeutics Initiates Clinical Development of AVX70371, a Hepatitis B immunotherapy using Launch-iT technology Multiple categories
07 May 2025 Remynd tests optimized septin modulator against Alzheimer’s disease in phase 1 clinical trial Multiple categories
28 Apr 2025 argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
